CB-011 is an off-the-shelf, allogeneic anti-BCMA CAR-T cell therapy developed by Caribou Biosciences for the treatment of relapsed or refractory multiple myeloma. CB-011 is manufactured from healthy donor T cells and engineered ex vivo using Caribou’s CRISPR-based platform (Cas12a chRDNA) to incorporate an immune cloaking strategy, including knockout of the B2Mgene and insertion of a B2M-HLA-E fusion protein, designed to reduce host immune recognition and rejection of the allogeneic CAR-T cells. The therapy is intended to provide a readily available, single-dose treatment option without the manufacturing delays associated with autologous CAR-T therapies. CB-011 is being evaluated in the Phase 1 CaMMouflage clinical trial and has received FDA Fast Track and Orphan Drug designations.
Disease: Relapsed or Refractory Multiple Myeloma, MM, (NCT05722418)
To see all details you need to have a subscription token. Click here for more details
Candidate summary:
Disease/Disease category:
- Haematological malignancies (blood cancers)
Official title:
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Phases:
- Phase 1
Status:
Active recruiting
Country:
- United States
